2.68

2.90% -0.08

After Hours: 2.67 -0.01 -0.37%

Fate Therapeutics Inc (FATE)

Overview News Price History Option Chain Financials Discussions Forecast

Fate Therapeutics Inc stock is traded at $2.68, with a volume of 1.28M. It is down -2.90% in the last 24 hours and down -16.77% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Previous Close:

$2.76

Open:

$2.81

24h Volume:

1.28M

Relative Volume:

1.05

Market Cap:

$294.37M

Revenue:

$12.32M

Net Income/Loss:

$-175.72M

P/E Ratio:

-1.235

EPS:

-2.17

Net Cash Flow:

$-141.45M

1W Performance:

-1.47%

1M Performance:

-16.77%

6M Performance:

-33.99%

1Y Performance:

+12.13%

1-Day Range:

$2.495

$2.81

1-Week Range:

$2.27

$2.81

52-Week Range:

$1.91

$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name

Fate Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (680)

Phone

858.875.1803

Address

12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA

Employee

181

Twitter

@fatethx

Next Earnings Date

2024-11-06

Latest SEC Filings

FATE's Discussions on Twitter

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral
Jan-06-23	Downgrade	Stifel	Buy → Hold
Jan-06-23	Downgrade	Truist	Buy → Hold
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-10-22	Initiated	Canaccord Genuity	Buy
Aug-18-22	Resumed	Wells Fargo	Overweight
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-11-22	Resumed	BMO Capital Markets	Market Perform
Dec-15-21	Upgrade	Wedbush	Neutral → Outperform
Dec-07-21	Initiated	Cowen	Outperform
Nov-09-21	Upgrade	Citigroup	Neutral → Buy
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight
Jun-07-21	Upgrade	H.C. Wainwright	Neutral → Buy
May-07-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Jefferies	Buy
Feb-26-21	Initiated	BofA Securities	Buy
Feb-26-21	Downgrade	Wedbush	Outperform → Neutral
Feb-11-21	Downgrade	Citigroup	Buy → Neutral
Jan-27-21	Resumed	H.C. Wainwright	Neutral
May-13-20	Initiated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-09-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-30-19	Reiterated	Mizuho	Buy
Dec-09-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-12-19	Initiated	SunTrust	Buy
Nov-06-19	Downgrade	Wells Fargo	Outperform → Market Perform
Oct-01-19	Initiated	Stifel	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	Cantor Fitzgerald	Overweight
Jul-12-19	Initiated	Oppenheimer	Outperform
Jun-13-19	Initiated	Mizuho	Buy
Jun-07-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Buy
May-24-19	Resumed	Citigroup	Buy
Mar-28-19	Initiated	SVB Leerink	Outperform
Jan-03-19	Downgrade	Stephens	Overweight → Equal-Weight
Nov-05-18	Initiated	Jefferies	Buy
Aug-01-18	Initiated	Citigroup	Buy
Mar-06-18	Downgrade	H.C. Wainwright	Buy → Neutral

View All

Fate Therapeutics Inc Stock (FATE) Latest News

Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024

Oct 25, 2024

Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St

Oct 25, 2024

Oct 22, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne

Oct 22, 2024

Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024

Oct 16, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat

Oct 16, 2024